The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...

For many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

SpringWorks Therapeutics (NASDAQ:SWTX) jumped 10% in premarket trading after the firm reported its Q4 results and canceled ...

German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

SpringWorks Therapeutics (SWTX) and Jennifer Fisher are collaborating to increase understanding of desmoid tumors as well as to encourage ...

Experts noted that rapid and extreme weight loss can introduce unique risks, such as a weakened immune system and malnourishment, as well as potentially too much muscle loss. They’re also concerned ...

A pharma giant expresses interest in a Stamford biotech company after striking a deal worth up to $1.3 billion for a New ...

thyssenkrupp nucera AG & Co. KGaA (ETR:NCH2) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. thyssenkrupp nucera KGaA delivered a ...

Revenue: €229.8m (down 1.0% from 1Q 2024). Net income: €28.9m (down 35% from 1Q 2024). Profit margin: 13% (down from 19% in 1Q 2024). The decrease in margin was primarily driven by higher ...

SWTX stock opened at $57.43 on Wednesday. The company has a market cap of $4.27 billion, a price-to-earnings ratio of -14.80 and a beta of 0.81. SpringWorks Therapeutics has a twelve month low of ...

Merck’s interest in SpringWorks — and its purchase of Yale spinout Modifi Biosciences this fall — are signs that Connecticut’s pharma cluster is maturing and growing even in an uncertain ...